** Brokerage Evercore ISI says Johnson & Johnson's JNJ.N Q4 medtech revenue was generally in line with estimates "with strength in vision/hips offset by softer electrophysiology and advanced surgery"
** J&J reports medtech Q4 revenue of $8.19 bln vs analysts' estimates of $8.22 bln
** Brokerage says co's Q4 U.S. organic revenue growth of 2.1% in its electrophysiology $(EP)$ segment is "soft", says share losses to Boston Scientific BSX.N and Medtronic MDT.N from their ongoing PFA launches "will be a focus"
** A pulsed field ablation system (PFA) is a type of heart device to treat certain abnormal heart rhythm conditions
** Medical device maker Abbott ABT.N also reported Q4 organic sales growth of 8.8% in its EP segment, which Evercore says "seems to be holding slightly better" than J&J
** Brokerage adds J&J's soft growth in its spine segment bodes well for other device makers Stryker SYK.N, Zimmer Biomet ZBH.N, Enovis ENOV.N and Medtronic
** J&J fell 7.7% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.